Matching articles for "Monjuvi"
Issue 1682 · August 7, 2023 Free
In Brief: Tafasitamab (Monjuvi) for Diffuse Large B-Cell Lymphoma (online only)

Tafasitamab-cxix ( Monjuvi – Morphosys), a CD19-directed cytolytic antibody, has received accelerated approval from the FDA for use in combination with lenalidomide (Revlimid) for treatment of relapsed or…

Med Lett Drugs Ther. 2023 Aug 7; 65(1682):e133 doi:10.58347/tml.2023.1682d
Tafasitamab-cxix ( Monjuvi – Morphosys), a CD19-directed cytolytic antibody, has received accelerated approval from the FDA for use in combination with lenalidomide (Revlimid) for treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from low grade lymphoma, in adults who are not eligible for autologous stem cell transplant. Accelerated approval was based on overall response rates.